116 related articles for article (PubMed ID: 36436079)
1. Estrogen receptor α K303R mutation reorganizes its binding to forkhead box protein A1 regions and induces chromatin opening.
Nakadai T; Yang L; Kumegawa K; Maruyama R
Mol Biol Rep; 2023 Feb; 50(2):1209-1220. PubMed ID: 36436079
[TBL] [Abstract][Full Text] [Related]
2. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
3. A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.
Herynk MH; Hopp T; Cui Y; Niu A; Corona-Rodriguez A; Fuqua SA
Breast Cancer Res Treat; 2010 Jul; 122(2):381-93. PubMed ID: 19842032
[TBL] [Abstract][Full Text] [Related]
4. Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice.
Herynk MH; Lewis MT; Hopp TA; Medina D; Corona-Rodriguez A; Cui Y; Beyer AR; Fuqua SA
Oncogene; 2009 Sep; 28(36):3177-87. PubMed ID: 19561644
[TBL] [Abstract][Full Text] [Related]
5. Decreased responsiveness of naturally occurring mutants of human estrogen receptor alpha to estrogens and antiestrogens.
Komagata S; Nakajima M; Tsuchiya Y; Katoh M; Kizu R; Kyo S; Yokoi T
J Steroid Biochem Mol Biol; 2006 Jul; 100(1-3):79-86. PubMed ID: 16713253
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
7. Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression.
Chen D; Parker TM; Bhat-Nakshatri P; Chu X; Liu Y; Wang Y; Nakshatri H
Oncogene; 2021 Feb; 40(7):1332-1346. PubMed ID: 33420376
[TBL] [Abstract][Full Text] [Related]
8. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.
Kong SL; Li G; Loh SL; Sung WK; Liu ET
Mol Syst Biol; 2011 Aug; 7():526. PubMed ID: 21878914
[TBL] [Abstract][Full Text] [Related]
9. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
10. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells.
Erdős E; Bálint BL
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.
Barone I; Iacopetta D; Covington KR; Cui Y; Tsimelzon A; Beyer A; Andò S; Fuqua SA
Oncogene; 2010 Apr; 29(16):2404-14. PubMed ID: 20101208
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.
Wu Y; Li Z; Wedn AM; Casey AN; Brown D; Rao SV; Omarjee S; Hooda J; Carroll JS; Gertz J; Atkinson JM; Lee AV; Oesterreich S
Mol Cancer Res; 2023 Jun; 21(6):591-604. PubMed ID: 36930833
[TBL] [Abstract][Full Text] [Related]
13. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response.
Laganière J; Deblois G; Lefebvre C; Bataille AR; Robert F; Giguère V
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11651-6. PubMed ID: 16087863
[TBL] [Abstract][Full Text] [Related]
14. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2.
Ahmed S; Al-Saigh S; Matthews J
Mol Cancer Res; 2012 May; 10(5):636-48. PubMed ID: 22596188
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
17. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979
[TBL] [Abstract][Full Text] [Related]
18. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
Barone I; Cui Y; Herynk MH; Corona-Rodriguez A; Giordano C; Selever J; Beyer A; Andò S; Fuqua SA
Cancer Res; 2009 Jun; 69(11):4724-32. PubMed ID: 19487288
[TBL] [Abstract][Full Text] [Related]
19. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer.
Irish JC; Mills JN; Turner-Ivey B; Wilson RC; Guest ST; Rutkovsky A; Dombkowski A; Kappler CS; Hardiman G; Ethier SP
Mol Oncol; 2016 Jun; 10(6):850-65. PubMed ID: 27005559
[TBL] [Abstract][Full Text] [Related]
20. Unique ERalpha cistromes control cell type-specific gene regulation.
Krum SA; Miranda-Carboni GA; Lupien M; Eeckhoute J; Carroll JS; Brown M
Mol Endocrinol; 2008 Nov; 22(11):2393-406. PubMed ID: 18818283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
